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Abstract
The recent years have witnessed an increased activity in biocompatibility research aimed at
limiting biomaterial-induced blood coagulation. From 2008 to 2016, a total of $36,946,764.00
USD was awarded in grants to 213 research proposals and as large as 50.4% ($18,627,854.00)
of that award monies were distributed to 101 proposals over the fiscal years of FY14 to FY16
alone. However, the complexity in blood responses to biomaterials, variability in blood
function between individuals and animal species, and differences in medical device
application and test setting all continue to pose difficulties in making a breakthrough in this
field. This review focuses on the remaining challenges in the context of biomaterial surface
interaction with blood, biomaterial properties and their influence on coagulation, old and new
surface anticoagulation methods, main test systems (complement and platelet function) for
evaluating those methods, limitations of modification techniques, and the current state of
systemic anticoagulation usage as adjunctive therapy for controlling blood coagulation on
biomaterials. Finally, we propose ingredients necessary for advancing the field towards
achieving totally local surface anticoagulation on blood contacting devices including
standardization of in vitro and in-vivo test methods. Some highlights of recent forwardlooking work and articles on local anticoagulation are also presented.
1. Introduction
Large quantities of blood-contacting medical devices with procoagulant surfaces are
used annually world-wide.[1, 2] It is estimated that more than 200 million of these devices are
utilized in patients in the U.S alone.[3] They range from devices with small surface areas like
catheters, vascular grafts, heart valves, cannulas, glucose, lactate sensors, and stents to those
with moderate surface areas like pacemakers, artificial kidneys, and left ventricular assist
devices. Then there are those with relatively larger surface areas like the artificial lungs,
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artificial hearts, and extracorporeal membrane oxygenation circuits. The surfaces of these
devices are made up of artificial materials that are different from endothelial cell surfaces,
which interface with flowing blood.[4−6] Among other features, these cells express enzymes
and secrete nitric oxide that maintains blood tone.[7−10] For example, nitric oxide inhibits clot
formation while thrombolytic enzymes break down formed clots. For artificial materials, these
properties are absent and rapidly activate blood into clots upon contact.[11,12] For bloodcontacting devices, clot formation can cause cessation of blood flow and lead to device
failure.[13−15] Moreover, devices that do not fail may release clots into the systemic circulation
and cause embolic complications.[14,16−18] In life support devices these clots can result in
morbidity and mortality. For instance, a small bore vascular graft serving as a coronary artery
may occlude from clot formation and cause myocardial infarction (heart attack). With
artificial lungs, clotting is especially problematic as they have relatively large surface areas
(1.3-2 m2) and a period of usage lasting from several weeks to months. Other clot-related
problems with artificial lungs include increased device resistance to blood flow and reduced
mass transport across their gas exchange membranes and they will typically fail after 7-14
days with accompanying hemorrhagic complications.[13−15,18] As a result, their usage is limited
with no solution in place for permanent lung replacement. Catheters without soluble heparin
locking, on the other hand, have limited a lifespan and do not reliably allow repeated
sampling of blood or continuous pressure monitoring in patients as their small lumen
diameters make them more prone to failure by clots.[19−22]
This review will look at some of the major anticoagulation approaches in clinical and
experimental use over the last two decades. It will also focus on some of the remaining
important and practical aspects of blood/biomaterial compatibility and problems with
compatibility testing as well as keys to improving the blood-contacting artificial surface so
that systemic anticoagulant drugs do not play a major role. Totally local anticoagulation on
blood contacting devices is achievable and may be realized in the near future with robust
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multifunctional artificial surfaces. These next generation surfaces will be rendered nonfouling/anti-clotting and remain so either through a single modification method that is stable
to hemodynamic and hemochemical interactions or, more realistically, through multimechanistic techniques. The latter approach will interrupt clot formation at both the contact
and propagation phases of the coagulation cascade.
2. Biomaterial Surface and Blood Interaction
Under normal physiologic conditions, a delicate balance between thrombus formation
and destruction is sustained by a complex series of mechanisms and interactions among
platelets, the vascular endothelium, the coagulation cascade, and the fibrinolytic system.[23]
Blood remains, under healthy hemostasis, in contact only with the normally antithrombogenic endothelium that is lined with cells which prevent adhesion, aggregation, and
activation of platelets, preclude the activation of the coagulation cascade, and modulate
hemostasis through the expression and secretion of a spectrum of molecules.[24] Among these
factors are prostaglandin, nitric oxide, thrombomodulin, heparan sulfate, tissue plasminogen
activator (t-PA), urokinase plasminogen activator (u-PA) and plasminogen activator
inhibitors.[11] Thrombomodulin combines with thrombin and the resulting complex activates
protein C which acts, upon its binding with protein S, as a brake on the coagulation cascade
by inactivating FVa and FVIIIa. Also, heparan sulfate inhibits blood coagulation by binding
and activating anti-thrombin, which is the main inhibitor of thrombin and FXa. Moreover, the
tissue factor pathway inhibitor (TFPI) inhibits the TF–FVIIa complex by forming a
quaternary complex TFPI–TF–FVIIa–FXa.[25] While the aforementioned factors inhibit blood
clotting, t-PA, u-PA, and plasminogen activator inhibitors modulate fibrinolysis.[26]
Endothelial cells also have a low surface energy that keeps blood proteins from changing
conformation.[25] However, when the continuity of the healthy endothelium is disrupted, for
instance upon an endothelial injury, this non-thrombogenic surface is transformed into a
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thrombogenic one[24], and a thrombotic reaction starts on the cells' subendothelium matrix and
on the connective tissues which get exposed[27]. Circulating platelets then adhere to these
structures and start the hemostatic process.[27]
In contrast to the healthy endothelium, artificial surfaces lack such endothelial properties, and
thus implants, whether intended for short term use (stents, catheters, heart valves) or long
term applications (extracorporeal circulation), face a challenge, when in contact with blood, to
oppose the natural coagulation process that becomes activated. Thrombus formation is a
common cause of failure of blood contacting medical devices since artificial biomaterials
promote clotting through a complex series of interconnected processes that include protein
adsorption, adhesion of platelets, leukocytes, and red blood cells, thrombin generation, and
complement activation.[24]
Coagulation on biomaterials is initiated by the contact system through the activity of
three main zymogens produced by the liver. These zymogens, namely Factor XII (hageman
factor), Factor XI, and high molecular weight kininogen (HK) all exist in plasma, and upon
contact with artificial surfaces, they go through the adsorption, initiation, and activation
phases.[11] In the activation phase, zymogen Factor XII first adsorbs to negatively charged
surfaces and activates to FXIIa by autoactivation. This process cleaves a single disulfide
bridge of FXII allowing its heavy chain to bind to the surface while revealing its active site.
At this point, FXIIa becomes a co-factor for prekallikrein (PK) and FXI which exist in plasma
as non-covalent complexes with HK (PK-HK and XI-HK). The PK-HK complex binds to
FXIIa to activate prekallikrein into kallikrein. The FXI-HK complex also binds to FXIIa to
activate factor FXI into FXIa to complete the activation phase of the contact system.
Zymogens XII, XI, and PK at this point have been activated into XIIa, XIa and K enzymes.[11]
Once activated, the contact system uses a positive feedback mechanism potentiated by
kallikrein. Kallikrein acts on FXII and HK substrates to speed up their conversion into FXIIa
and HKa. For example, HKa binds 10 fold faster than HK to PK and FXI thereby accelerating
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the association PK and FXI. This feedback mechanism serves as the initial driver of all
amplification reactions in blood coagulation starting from the contact system down to a
formed clot. In addition to the positive feedback mechanism, the contact system also has a
negative feedback arm to modulate itself. During negative feedback control, Kallikrein
cleaves off a fragment of adsorbed FXIIa, (FXIIf), into plasma leaving behind inactivated
FXIIi. Although FXIIf is still active, its participation in blood coagulation is decreased as it
loses its affinity for surfaces. It, therefore, exhibits low activity for prekallikrein to kallikrein
conversion. FXIa is also a player for the suppression of contact activation. It cleaves off the
light chain of adsorbed HK, HKlc, which contains the active site of HK leaving behind the
heavy chain portion (HKhc). This reaction terminates the cofactor activity of HK and thus
allows FXIa to desorb from the artificial surface.[11] The effect of the negative feedback
mechanism has, however, not inhibited the contact system adequately to prevent downstream
activation of pro-coagulant factors in the intrinsic and extrinsic pathways of the coagulation
system that lead to clot formation in blood-contacting devices.
Post contact-system blood coagulation has been traditionally viewed in two separate
pathways; the intrinsic and extrinsic pathways. Such views have essentially faded as it is now
more accepted that the pathways interact in vivo. The contact system is viewed as part of the
intrinsic pathway because it initiates that branch of blood coagulation. The intrinsic pathway
is associated with artificial surfaces and consists of reactions involving only vascular elements
that can occur independently of factor VIIa whereas the extrinsic branch consists of blood in
addition to vascular elements. The main difference between the branches lies in the way they
activate FIX. The intrinsic system uses FXIa in the presence of Ca2+ whereas the extrinsic
system requires tissue factor (TF) usually embedded in the cell membrane lipid bilayer in
addition to calcium.
The intrinsic pathway is initiated by the activation of IX to IXa by Factor XIa which is
activated in the contact system. FIX can also be activated by TF in the presence of a
6

phospholipid (PL) surface and cofactor VIIa. For the next reaction to occur, calcium, FIXa
together with the tenase complex (phospholipid surface-cofactor VIIIa) must work together to
activate FX. This marks the end of the intrinsic pathway.[11,26]
Activation of the extrinsic pathway is achieved again by TF in the presence of PL and VIIa,
the same coagulant elements association utilized in the intrinsic pathway. As TF is present in
the endothelial tissue, activation of the intrinsic pathway is usually associated with tissue
damage. However, biomaterial-induced platelet activation and inflammation can also activate
the intrinsic branch, as TF is also present in platelets and leukocytes. When TF associates with
a PL and cofactor VIIa, FX is activated into FXa marking the end of the extrinsic pathway
and the beginning of the common pathway of blood coagulation.[11,26]
The common pathway is activated by the prothrombinase complex consisting of FXa, cofactor
Va on platelets’ membranes and a PL surface in the presence of calcium. With FVa serving as
the platelet membrane receptor for FXa, the activated platelet produces and secrets
prothrombin. The complexing of these four elements to form prothrombinase increases
prothrombin activity by 300,000 fold compared to that achieved by FXa and prothrombin
alone. Adsorbed and activated platelets on the artificial surface, at this point, are connected by
fibrinogen-glycoprotein IIb/IIIa platelet membrane receptor bridges following cleavage of
fibrinopeptide A and B from fibrinogen. Platelet aggregation achieved by interconnectingplatelet- secreted fibrinogen bridges is still a premature clot until thrombin crosslinks the
platelet aggregate by converting fibrinogen into longer fibrin strands that bind to activated
platelets multiple times. Finally, a solid clot is formed when thrombin activates FXIII to
FXIIIa to cross link the interconnecting fibrin. This creates an insoluble fibrin network which
is the end point of both coagulation pathways. Thrombin has a dual role in haemostasis, as in
addition to facilitating the fibrin network formation. It also functions as an activator of two
distinct platelet receptors, namely the protease activated receptors (PARs) 1 and 4. It also
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potentiates the clotting process by activating FV, FVIII and FXI. It is therefore viewed as the
most potent clotting factor in blood coagulation.[28]

2.1. Platelet Activation
Circulating platelets are activated either after damage to healthy endothelium or after
blood exposure to an artificial surface. After damage to the endothelium for whatever reason,
the endothelium loses its integrity and has to remedy its environment in order to restore its
vascular tone. To achieve normal haemostasis, ruptured endothelial cells secret a” sticky”
protein called von Willebrand factor (vWF) to bind to collagen in the exposed sub-endothelial
layer so that circulating platelets can bind to the opposite ends of vWF to form a seal at the
damaged area.[11,26] Glycoprotein Ib/IX receptor on platelets membrane allows binding of
vWF to activate platelets. On artificial surfaces, the contact system activation leads to the
generation of FXa. This, in turn, binds to FVa on platelet membrane to activate platelets.
After the initial phase where few platelets are activated, a second and massive platelet
activation phase ensues. The release of clotting factors from platelets’ granules during the first
wave of activations acts to systemically activate substantially large amounts of circulating
platelets to potentiate coagulation. For instance, Activated platelets will secrete abundant
Adenosine diphosphate (ADP) and Adenosine triphosphate (ATP) from their dense granule
that in turn can activate neighboring platelets via ADP and ATP sensitive receptors. ADP is a
ligand to the receptors P2Y1 and P2Y12, located on the platelet surface.[29-30] Among the
granule content released, those of greatest physiological importance and their platelet
membrane receptors, for example, are listed in Table 1.
Shear rate from vascular blood flow can also influence blood coagulation. At high
shears platelets undergo conformational changes and release their pro-coagulant factors
including vWF, which propagate clot formation- a mechanism different from activation by
chemical induction. Typical shear rates in human body range on the order of 10 s-1 to 1500 s-1
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corresponding to 1 dyn/cm2 to 55 dyn/cm2. The larger vessels (veins and arteries) tend to have
lower shear rates than the smaller ones.[31-34] For instance, the vena cava (larger diameter) will
have smaller shear rate (10 s-1) than venules (375 s-1) and the ascending aorta (larger
diameter) will have a smaller shear rate (250 s-1) than arterioles (~1500 s-1). Moreover, arterial
flows are of higher shear rates (125 s-1 to 1500 s-1) than venous flows (10 s-1 to 375 s-1).
These flow variations present a range of shear rates to which surfaces of blood-contacting
devices can be exposed depending on where they are implanted. In a high shear rate
environment, proteins and cells are highly mobile from momentum transfer and their
deposition can be swept away before they amass into macro-aggregates whereas in low shear
regimes seen in some blood-contacting deivces, continuous deposition and increased
surface/biofoulant interaction can lead to larger blood clots and faster coagulation effects.
Case in point, it has been reported that densely networked fibrin morphology is formed on
surfaces exposed to low shear rates 10 s-1 compared to low to no discernable fiber deposition
from 25 s-1 to 100 s-1 shear rates.[35] However, with respect to platelet activation, recent
experiments have elucidated new platelet aggregation kinetics that led to artirial occlusion
from large thrombi formation due to local release of vWF from platelets and conformational
changes of platelets.[36] These clots were formed under high shear stress arterial blood flow,
and their histological analyses showed high platelet to red blood cell ratio compared to low
shear venous blood flow experiments. Clearly, continued efforts to elucidate hemostatis as a
function of stress regimes, composition of blood, cellular and molecular environment of the
vasculature, and other factors are important. Implications of increasing our understanding here
will broadly impact medicine, as acute thrombotic events can be better controlled, bloodcontacting device design and testing will be better informed, and their clinical performance
can be enhanced.
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2.2 Complement Activation
Several polymer surfaces were reported to have a strong influence on contact
activation and in consequence also on the activation of coagulation and complement systems.
Much research has shown that upon exposure to blood, the artificial surface becomes rapidly
covered by a protein layer from different cascades and the deposition of this layer triggers the
activation of the contact, coagulation and complement pathways. For instance, the adsorbed
fXII and fibrinogen constituents of this layer trigger the activation of the complement, and
one of its components, C3 is prone to undergo conformational changes upon binding to that
layer leading eventually to the activation of the complement alternative pathway. It has also
been shown that activation products of the contact activation system (Factor XIIa [FXIIa] and
kallikrein), as well as thrombin and plasmin, are able to cleave purified complement
component or fragments thereof in vitro.[37-41] Recently, these early observations have been
confirmed and extended, and more factors have been added to the list of proteases that are
potentially able to bypass convertases and directly generate complement protein
anaphylatoxins C3a and C5a respectively, leading eventually to the activation of the
complement alternative pathway. Whereas the incubation of C3 or C5 with FIXa, FXa, FXIa
thrombin, and plasmin resulted in the release of C3a and C5a, respectively, the coagulation
factor XIIa is able to activate the complement complex C1 initiating the classical pathway.
Thus, there is a crosstalk between the components of the coagulation and complement
cascades, and the activation of the complement on top of the adsorbed protein layer leads to
the generation of the c3a and c5a that recruit and activate polymorphonuclear leukocytes and
monocytes.[38-41]
3. Biomaterial surface properties and their influence on coagulation
Immediately following the contact of blood with synthetic materials, spontaneous adsorption
of proteins, a phenomenon termed “fouling” occurs leading to an advanced adverse biological
response afterwards. [42] In general, antifouling surfaces are based on minimizing the
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intermolecular forces of interactions between extracellular biomolecules and the synthetic
surface so that cells do not adhere or an adhered cell is easily released under low shear
stresses. A truly antifouling surface, also referred to as a ‘stealth surface’, remains undetected
by cells in a biological milieu, and is therefore not prone to biofouling.[43] The interfacial
energy between a surface and water is expected to play an important role in conferring
antifouling characteristics to the surface. To better understand fouling phenomena
theoretically, Baier related fouling with surface energy.[44] A surface is referred to as a theta
surface if when glycol-proteinaceous macromolecules encounter such surface, they have the
least probability of getting denatured.[44] Theoretically, minimal bio-adhesion occurs at a
critical surface tension in the range[45] of 20-30 mN/m preferably between 22 and 24 mN/m
which is approximately equal to the dispersive component for water.[46] In a pioneering study
on the structure-property relationship of surfaces in resisting protein adsorption by
Whiteside’s,[47] it was reported that to resist adsorption of proteins a surface needs to exhibit
four molecular-level characteristics: hydrophilicity, hydrogen-bond acceptors, do not include
hydrogen-bond donors, charge neutral overall. There are very few exceptions such as
mannitol groups, which resist protein adsorption although they are hydrogen-bond donors.[48]
Hydrophilic surfaces such as poly(2-hydroxyethyl methacrylate) (PEGMA) have interfacial
energy below 5 mJ/m2.[49] Although the mechanism of action for PEG’s nonfouling is not
fully understood[50], it is generally accepted that PEG’s effectiveness is due to the steric
repulsion effect with loss in entropy exhibited by a PEG-coated surface when proteins attempt
to adsorb.[51,52] In contrast, non-polar hydrophobic surfaces exhibit high interfacial energy
with water. When such surfaces are in contact with biological media, amphiphilic
biomolecules such as proteins show significant adsorption to minimize the interfacial energy
of such surfaces.[49] For example, when zoospores of Ulva are exposed to alternatively
patterned hydrophilic and hydrophobic arrangement of self-assembled monolayers (SAM),
zoospores preferred to settle on hydrophobic patterns.[53] For effective nonfouling, in terms of
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surface complexity[49] a surface can be homogeneously hydrophilic (nonfouling), hydrophobic
(foul and release if elastic) or amphiphilic (to ‘confuse’ bioorganisms).[54,55] In addition,
surface texturing can also provide useful nonfouling properties as in the case of biomimicking
shark-skin inspired PDMS coating using the Sharklet AFTM microtopography.[56] Surface
modification is arguably the most convenient and effective method of imparting nonfouling
properties to the material. As per the criteria established by Whitesides[47,57,58] PEG is the
prominent candidate for nonfouling applications.[47,58,59] However, PEG polymers are prone to
oxidation and may have issues with long term applications especially in water.[60] Among
several possible polymers, zwitterionic polymers recently emerged as prominent
candidates.[61] Due to their strong binding with water, zwitterionic polymers are very effective
nonfouling materials and have been well studied by the Lin, Ishihara, and Jiang groups.[61-64]
These hydrophilic polymers can be attached to a surface to impart nonfouling behavior, and
they can be attached to surfaces by various methods;[65] “graft from” in which an initiator is
attached to a surface from which the polymer is grown, “graft to” in which a functional chainend polymer can be grafted, and adsorption of block copolymers. A variety of methods need
to be attempted for a given polymer as the nonfouling behavior of the modified surface
depends on the graft density and thickness of the given polymer.[43] Atom Transfer Radical
Polymerization (ATRP) is one the most widely used method for both “graft from”[66,67] and
“graft to” techniques for zwitterionic polymers[68,69] and PEG modification.[70-72] Zwitterionic
grafts typically will form brush or mushroom configurations on the polymer substrate
depending on graft chain separation distance. In a brush configuration, the zwitterionic
polymer grafts are in close promixity that they extend away from the substrate to repel
macromolecules including proteins. In a mushroom configuration, the surface polymers
chains are separated by larger distances such that they expand into non-extended dimensions.
The larger average separation distance between chains provide room for macromolecules to
interact directly with the surface of the substrate. Hence brushes tend to be anti-fouling while
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mushrooms tend to be fouling [43]. Protein resistance of these surface give an indication about
their nonfouling behavior for real world biofouling applications. It is necessary that long term
studies of different polymers in blood contacting applications be performed to select materials
for demanding applications.[73]
4. Surface Anticoagulation Approaches
Modification approaches developed to combat clot formation on blood-contacting
artificial surfaces have focused on usage of single-mechanistic anti-clotting processes through
a variety of hydrophilic coatings to prevent non-specific protein adsorption by biomaterial
surface hydration, nitric oxide release from polymers to inhibit platelet activation, and most
recently via dual-mechanistic experimental means. Table 2 presents these methods, their
mechanisms of action, limitations, and relevant commentary about their usage.
4.1 Limitations of Approaches
Several limitations associated with anti-clotting surface modification approaches
discussed in Table 2 still challenge the field and these problems need to be solved in order to
design truly hemocompatible surfaces. And such limitations must be addressed using all
plausible alternatives including methodical incremental approaches. In the following section,
limitations of commonly used coatings are further reviewed.
In heparin coatings, the challenge is that each heparin polymer must first attach to an
antithrombin III (ATIII) serine protease inhibitor to work. The formed heparin-ATIII complex
must then binds to procoagulant thrombin to deactivate it from propagating coagulation.
Realistically, this scenario does not always occur due to the surface-immobilized state of
heparin. Another limitation of the heparin arises from its degradation due to stresses imposed
by its biological surrounding, and it gradually loses its availability to complex with
ATIII.[37,74,75]
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Hydrophilic coatings ranging from Sorin to Trillium increase the hydrophilicity of
surfaces and also lower surface energy. Although these mechanisms lead to minimal protein
adsorption, the coatings are prone to leaching due to environmental factors which lead to loss
of water retention. Similarly, hydrogel and ionic liquid based coatings are shown to be highly
resistant to protein adsorption and even blood progressively lose their bioactivity. Despite
notable advantages of these coatings, their acute and chronic inflammatory responses in vivo
have been inconsistent. Fluoro-containing coatings, on the other hand, minimize surface
energy and lower surface tension[76], and have been shown to inhibit fouling from whole
blood in in vitro and acute in vivo studies.[77] In vitro testing result also showed that liquid
perfluorocarbons can be displaced from the surface under hydrodynamic shear stress.[77]
It should be noted that while the theory of surface energies was found to be important in
single protein/model surface interaction study, it is a big leap to apply only this theory to the
explanation of whole blood interaction with polymers in medicine. Poly (ethylene oxide)
(PEO), otherwise known as polyethylene glycol (PEG) is a hydrophilic polyether used as
coatings on blood contacting medical devices. It is made up of a structured repeat unit (CH2CH2-O) that drive surface hydration lowers protein adsorption on devices. Positive results
have been shown in in vitro testing with some reports arguing for inconsistent results.[75]
Nevertheless, polyethyleneglycol has been applied as coating for biocompatibility studies on
many surfaces including polymers (polyurethanes), metals (stainless steel) and as conjugants
of drugs to improve their bioavailability. It is known to increase the hydrophilicity of surfaces
which in turn reduces nonspecific attachment of proteins[78,79]. The hydrophilicity is typically
screened by contact angle measurements which are often correlated to resistance to biofouling.
Lower contact angles (72.1° from 99.6°) have been observed from PEG-grafted thermoplastic
polyurethanes[80-84] which reduced platelet and bacterial attachment and from PEG-grafted
stainless steel which reduced the adhesion of bovine serum albumin and Listeria ivanovii[85].
Moreover, PEG has been shown to prolong the in vivo circulation of drugs complexed to PEG
14

[86]

. The year 1990 marked the first of eleven FDA approved PEG conjugated drugs with the

last drug receiving such clearance in 2014.
An anti-inflammatory material can be applied as non-fouling surface while others are
delivered as anti-inflammatory agents. The latter technique allows proteins to passively
displace preadsorbed anti-inflammatory proteins.[87] Both approaches are influenced by
coating stability and more in vivo research is needed.
Biologically active surfaces, such as nitric oxide releasing polymers, are a relatively
new approach for improving blood/biomaterial compatibility. Nitric oxide is an antibacterial
and antiplatelet agent that is endogenously released into flowing blood at low flux levels (0.5
- 4 X10-10 mol/cm2/min)[88] by healthy endothelium and can be incorporated into polymers,
like polydimethylsiloxane (PDMS) via chemical conjugation reactions. The goal of this anticlotting material modification method is to attain flux levels comparable to what is produced
by the endothelium and at nontoxic levels. The ability to control the delivery of nitric oxide
and its duration of release continues to be under investigation, as long term release has also
not been achieved yet.
A much different antifouling surface modification approach which involves
endothelial cell (EC) attachment to artificial surfaces is achieved by first adding endothelial
cell receptors to the preferred non-biodegradable substrate followed by EC attachment.
Adequate and appropriate distribution of receptors as well as surface morphology of the
substrate are aimed at mimicking the extracellular matrix to promote interaction between the
ECs and EC cell receptors. Many of the difficulties associated with conjugating EC receptors
to substrates remain unsolved so alternative approaches using stem cells to induce
endothelialization are under investigation.[24] Biodegradable polymers such as poly(1,8-octane
diol citrate) (POC) are also being used as substrates to promote endothelialization. The
application of POC onto grafts (POC-ePTFE) has been shown to maintain EC adhesion and
proliferation of porcine cells similar to that of the native tissues, and within 10 days the EC
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was confluent, while only random patches were evident on ePTFE controls.[24] For such
substrates, it is important to maintain an optimum balance between polymer degradation and
cells growth and replication rates, as these factors including porosity influence the polymer’s
performance and endothelialization. The use of self-assembled monolayers (SAM) to study
antifouling materials are a unique approach as they provide a controlled protocol for
evaluating and screening for resistance non-specific protein fouling. The typical substrate for
SAMs is, however, gold, which is not a medical relevant surface such polyurethane,
polydimethylsiloxane, or 316 stainless steel.
Surfaces coated with albumin have demonstrated increased resistance to platelet
adhesion,especially when compared to other proteins found in human blood. The protein can
be covalently attached to the surfaces or selectively adsorbed onto surfaces modified with
PEO-tethered warfarin which increases the surface affinity for endogenous albumin.[75]
Hemocompatibility studies of albumin-coated surfaces have generally not shown success. A
clinical study examining prosthesis in aortic position[89], observed similar coated prosthesis
performance to uncoated controls.
On the other hand, elastin-inspired coatings which are materials containing elastin, a
protein found in connective tissue has been shown to limit platelet adhesion and aggregation.
However, due to its insolubility, it is difficult to isolate and purify elastin[75]. Another coating
inspired by proteins is the Phosphorylcholine (PC) which mimicks phosphatidylcholine found
in animal cell membranes. While surfaces with PC coating limit protein and cell adhesion in
vitro supposedly because of their zwitterionic nature and electrically neutral state at
physiologic pH, the relatively weaker van-der Waals forces that hold their monolayer or
bilayer coating molecules together create instabilities[75]. PC-coated surfaces have exhibited
reduced platelet adhesion in vitro but showed no benefit in some animal studies.[37]
Pyrolytic-carbon coating takes the concept of early carbon-coated surfaces and applies
it to a modern approach. The process occurs through chemical vapor deposition in which
16

hydrocarbon is heated and a graphite layer is crystallized as a ‘highly ordered layer of carbon
atoms‘.[75] Although pyrolytic-carbon coated surfaces were found to reduce platelet adhesion
on vascular graft, they did not affect their overall patency rate.
Needless the say many limitations exist among these antifouling coatings, and by
addressing these challenges and evaluating sound alternative approaches, while limiting the
risk of bleeding associated with systemic anticoagulant usage, further improvements in
blood/biomaterial compatibility can be achieved.
5. Current State of Systemic Anticoagulation Usage
Largely due to surface modification limitations discussed earlier, blood coagulation on
medical devices remains a challenge yet to be solved through surface/material modification
alone. Systemic anticoagulation drugs, especially heparin, are still required as adjunctive
therapies with the most commonly used systemic anticoagulant being heparin although other
agents such as clopidogrel, aspirin, and warfarin are also used. Heparin’s role in inhibiting
clots formation is multi-faceted acting through inhibiting factor Xa from activating
prothrombin into thrombin. When it binds the plasma protein antithrombin III, it directly
inhibits thrombin from binding to platelets, and the heparin-AT complex inactivates several
coagulation enzymes including thrombin, factors IXa, XIa, and XIIa.[26, 90] Heparin slows the
process of thromboplastin synthesis, decelerates the conversion of prothrombin to thrombin,
and inhibits the effects of thrombin on fibrinogen, blocking its conversion to fibrin. It also
causes an increase in the number of negatively charged ions in the vascular wall, which helps
prevent the formation of intravascular clots. In addition, heparin can act through other serine
protease inhibitors such as heparin co-factor II, protein C inhibitor and tissue factor
plasminogen inhibitor. The antithrombotic action of heparin in vivo is complex, and
interactions with different plasma proteins and cells play significant roles in the living
vasculature.
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Warfarin, a coumarin derivative, is considered among the most common vitamin K
antagonists (VKA) in which it generates its anticoagulation effects by affecting six vitamin Kdependent protein factors involved in the coagulation cascade (factors II, VII, IX and X and
proteins C and S).[91, 92] Warfarin and heparin work in slightly different ways, but both block
the production of certain cofactors in the liver that work together to promote blood to clot.
The points of action of both these anticoagulants are downstream of the onset of blood
coagulation and have no effect on protein adsorption. Furthermore, these anticoagulants may
compromise hemostasis and cause hemorrhage as they act systemically.[93, 94]
While Warfarin inhibits Factors II and VII of the extrinsic coagulation pathway, and
Factors IX, X, and prothrombin of the intrinsic pathway, heparin exerts its major effect via
antithrombin, converting antithrombin to a more efficient inhibitor of circulating thrombin
(factor IIa), factor Xa, factor IXa, factor XIIa, and kallikrein. However, due to the multiple
anticoagulant mechanisms of heparin, differential molecular weight-based clearance, heparin
resistance, and patient-specific characteristics (age, weight, gender, and tobacco), attaining
therapeutic anticoagulation is complicated. Moreover, the resultant under- or over-therapeutic
anticoagulation is associated with increased risks of ischemic and bleeding complications.
Therefore, it is important to maintain heparin anticoagulation within a relatively narrow
therapeutic range.[95] Also Heparin-induced thrombocytopenia (HIT), a condition
whichdecreases platelet count during or shortly following exposure to heparin[96], is
considered the most frequent drug‐induced type of thrombocytopenia and can lead to
significant morbidity and mortality if unrecognized. Heparin’s interaction with circulating
platelets lead to their activation followed by the release of their pro-thrombotic
platelet‐derived micro-particles, which causes platelet sequestration and consumption, and
eventually thrombocytopenia.[96,97]
In surgical procedures requiring cardiopulmonary bypass (CPB) or other blood
contacting devices, heparin is used to elevate the activated clotting time(ACT) increasing the
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activity of the anti-thrombin. Since some patients are AT deficient and thus have a diminished
heparin response, and accordingly fail to reach therapeutic ACT, the majority of them may
require AT replacement often with antithrombin III (ATryn, recombinant antithrombin III
[rhAT], rEVO Biologics).[98,99] In the same way, although Warfarin inhibits the activation of
the vitamin K–dependent clotting factors (Factors II, VII, IX, and X) and regulatory proteins
(proteins C, S, and Z), it is one of the leading drugs implicated in emergency room visits for
adverse drug reactions.The potential bleeding risk associated with its therapy have led to its
limited use especially in the elderly population. Currently, there exists no optimal dose[100] as
it is difficult to administer warfarin at the correct dose because of its narrow therapeutic index,
its tendency to cause bleeding, and the individual variability in patient response. Therefore,
achieving safe and effective doses of warfarin therapy is both an urgent and important
concern.
Recent research has focused on pharmacogenomics accounting for individual variation
in anticoagulant activity of vitamin K antagonists.[101] Attention has focused on singlenucleotide polymorphisms (SNPs) of genes that encode two proteins: the cytochrome P450
2C9 enzyme and vitamin K epoxide reductase complex (VKORC1).[102] Studies suggest that
CYP 2C9 influences warfarin metabolism and affects warfarin half-life, whereas VKORC1
plays a role in the pharmacodynamic response in expression of the enzymatic target of
warfarin. For instance, patients who carry CYP 2C9*2 and CYP 2C9*3 alleles tend to require
lower warfarin maintenance doses because of their slowed metabolism compared with
patients who carry the “wild-type” allele.[103,104]
Aspirin and clopidogrel are also among the commonly used systemic drugs to inhibit
platelet activation. Asprin irreversibly inhibits the synthesis of platelet- dependent
thromboxane A2 formation and prostaglandins inside platelets and clopidogrel binds to
platelets ADP receptor and P2Y12, to block ADP from activating platelets. They inhibit the
clotting cascade at the biomaterial’s surface and inside platelets in an irreversible manner and
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increase the risk of bleeding.[15,93] Many other studies report significantly higher postoperative
bleeding complications among patients with continued antiplatelet therapy with
clopidogrel.[105]
Aspirin is the "gold standard" antiplatelet agent for the prevention of arterial
thromboses. The optimum dose of aspirin as an antithrombotic drug can differ in different
organ circulations. While 100 mg/day is sufficient for prevention of thrombus formation in
the coronary circulation, higher doses may be required for the prevention of vascular events in
the cerebral and peripheral circulation. However, any effective antiplatelet dose of aspirin is
associated with an increased risk of bleeding and therefore, the individual benefit/risk ratio
determines the administration of the compound.[106]
The response to these systemic drugs differs from patient to patient. In fact, many
patients are resistant to the effects of a single oral anticoagulation drug, so a therapy that
embodies multiple drugs having different mechanisms of action is often used. One example of
this is the use of a multi-targeted antithrombotic approach, involving anticoagulation
(bivalirudin and warfarin) and antiplatelet therapy (dipyridamole and aspirin), in order to
mitigate the pro-coagulative effects of mechanical circulatory assist devices, particularly those
that are associated with the CardioWest[107] temporary total artificial heart.[108, 109] Still, the
problem with this approach is that although the mechanisms of action for current antiplatelet
agents are known, their combined effect may induce anticoagulation at magnitudes too large
to allow restoration to normal hemostasis. The administration of these agents concomitantly
can increase to risk of bleeding and lead to other unforeseen complications.[108] Careful
monitoring of this variant multisystem approach using tools such as efficacy tests, safety tests,
and warfarin genomics is therefore important for maximizing the therapeutic actions and
minimizing the bleeding risks that are associated with the technique. Ultimately, systemic
drugs increase the risk of bleeding complications because of their prolonged half-lives.
Bleeding complications become even more devastating in patients with renal insufficiency
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who cannot efficiently clear these long lasting drugs. The effects of systemic anticoagulation
swing from bleeding in cases where it overwhelms hemostasis to device clotting when
inadequate concentrations are used. In devices with large surface area, both effects (bleeding
and depletion of systemic clotting factors and platelets) can occur.
Bleeding complications from systemic heparinization are the most common and lifethreatening. For example, the Michigan ECMO experience with neonatal mortality is one that
can still be improved if bleeding complications due to systemic anticoagulation are reduced.
According to the most recent report on the impact of ECMO on neonatal mortality[109],
bleeding is the most frequent cause of death in newborns managed with extracorporeal life
support. In this population, intracranial hemorrhage occurred in approximately 13% of
neonates, 5% of pediatric patients, and 4% of cardiac patients. Clotting complications are also
common, occurring in 26% of patients.[110]
Conventional anticoagulants have somehow proven efficacy. However, due to the
narrow therapeutic window, the necessary need for regular monitoring, and other
complications, over the last decade or several decades, new oral anticoagulants (NOACs)
have been launched and developed.[111] These new oral anti-coagulants range from Factor Xa
inhibitors, such as apixaban and rivaroxaban, which selectively and directly bind to the active
site of factor Xa and thereby inhibiting both free and clot associated factor Xa, to direct
thrombin inhibitors (DTIs). DTIs inhibit the intrinsic activity of the thrombin. Unlike heparin,
which also inhibits thrombin, the DTIs do not require a factor and can inhibit thrombin
directly. These drugs, such as bivalirudin, are used for prophylaxis and treatment of venous
thromboembolism and acute coronary syndrome, and for prophylaxis of thrombus formation
in non-valvular atrial fibrillation.[112,113] They are also used as anticoagulation alternatives in
the setting of HIT.
These new oral anticoagulants show advantages compared with conventional
anticoagulants in the prevention and treatment of patients with thromboembolic events,
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especially because of lower rates of hemorrhagic outcomes [111-114], the rapid onset and offset,
short half-life, predictable therapeutic effect and wider therapeutic window in addition to the
need for no lab monitoring. Nonetheless, there are some conditions for which parental
anticoagulants remain the drug of choice. Despite the aforementioned advantages of NOACs,
these drugs are not ideal because their use is limited or contraindicated under some
circumstances. For example, none of the direct NOACs are approved-to-use drugs during
pregnancy or in babies and children.[111, 114] Additionally, NOACs have not yet been applied
in patients with mechanical mitral valve issues (with increased rates of thromboembolic and
bleeding complications),[111, 114] patients with malignant disease, and those with
antiphospholipid syndrome, which is associated with a greater risk of thrombophilic
states.[111,114] More studies are still required to evaluate and further assess the efficacy of
NOACs.
6. Keys to Achieving Totally Local Surface Anticoagulation
To advance the current status of surface anticoagulation it is critical that: novel surface
modification approaches are actively pursued, in-clinical-use and promising experimental
techniques are critically reviewed, limitations of the primary mechanisms of action of those
modification methods are clearly established, the potential for improving on those limitations
through reasonable optimization processes is assessed, and synergy benefits from colocalization of two or more anticoagulation properties on surfaces, an approach arguably of
most promise and which logically transitions from proven single mechanistic methods, are
evaluated. These are essential factors that need to be addressed in order to advance surface
anticoagulation research.
As discussed in preceding sections, there are several ways of organizing surfaces
which interact with blood and many are actively being researched. These surfaces have been
designed to remain passive and hydrophilic, active and hydrophilic, or active and antithrombogenic. On such designer substrates, we either rely on surface hydration to keep
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procoagulant blood factors away from settling on the surface or on coupling of soluble
proteins (e.g. non-dominant form of antithrombin III, beta-antithrombin III)[109] and enzymes
to surface-bound active agents such as heparin to inhibit activation of key procoagulant
elements like thrombin and factor X. There are also catalyzing surfaces such as copper (II)
doped polymers which catalyze the dissociation of nitric oxide from endogenous organic
compounds such as S-nitrosothiols[115- 117] (NO donors). In addition to these designer surfaces,
tailored polymeric matrix composites that secrete anti-clotting agents such as nitric oxide to
limit the activation of key procoagulant platelets have been extensively studied.[118- 123]
Due to the limited and generally short-lived benefits of surface modification approaches, as
deducible from the literature, an easier argument to make is that in-clinical-use approaches are
either not multi-inhibitory/adequate enough to keep blood-contacting surfaces free of clot
formation driven by redundantly complex set of reactions, or not robust to prevent loss of
effectiveness during weeks-long (> 2 weeks) exposure to blood flow. Nonetheless, it is
difficult to confidently conclude whether it is the case of adequacy or loss of function because
of the lack of proper scientific data. Some experimental methods, on the other hand,continue
to show outstanding resistance to nonspecific protein adsorption from the whole plasma [124127]

and in some cases to whole blood coagulation[77] although only in in vitro and in vivo

preclinical settings. For these surface modification techniques, their limitations have been
limited to acute in vivo studies at best. [77, 128-143]
Generally speaking, the optimization approaches to ensure the long-term function of
in-clinical-use and experimental approaches can be grouped into fortification processes that
impart stability to designer surfaces and controlled release of anti-clotting agents from matrix
composites. Optimized density grafting, covalent attachment strength between graft and
substrate materials, and reliable and appropriate measurement techniques to ensure ultra-low
fouling graft coverage, and stability against typical hemodynamic shear stresses presented to
implantable medical devices are needed in the fortification process of designer surfaces.
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Microenvironment control of matrix composites for tunable release of anti-clotting agents will
also play a major role in the optimization processes needed overcome current limitations of
blood-contacting surfaces.
Until then, it is reasonable to question whether single-mechanistic modification
methods can be fully optimized. And after fortification and micro-control of release agents,
can each method alone lead to totally local surface anticoagulation? As research leads us to
making such determination in the future, the potential of drawing synergy from multiple anticlotting agents must not be overlooked. The argument can be made for pushing the boundary
of surface anticoagulation research beyond the norm of single-mechanistic anti-clotting
surface modifications because of millions of years of evolution which have led to equipping
the luminal surface of healthy blood vasculature with several anticoagulation functions all
working in concert to maintain blood tone.
The significance of this approach is that there is already a wealth of knowledge about
many single-mechanistic surface modification approaches and their synergy can lead to
increased hemocompatibility of blood-contacting surfaces. Even a minor improvement in the
hemocompatibility could result in large upgrades in the patient-care environment.
In the following section, the mechanisms of action of a subset of the modification approaches
discussed earlier are assessed in pairs and triplets to draw otherwise not obvious conclusions
about their potential synergies toward developing a super anti-clotting material. For brevity,
only a few highly promising and in-clinical-use methods were included in our analyses in
Table 3. The anticoagulant functions of nitric oxide, zwitterionic coatings, polyethylene
glycol, and heparin coatings are paired and tripled and the resulting multi-mechanistic action
against clot formation are presented. NO’s presence on any of the combinations adds the
property of inhibiting platelet adsorption and activation. For example, NO release function
added to either zwitterionic[116] or PMEA[117] grafted surfaces reduce the adsorption of key
clotting elements (fibrinogen and platelets) at a significantly higher level than surfaces
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modified with either NO release or coating alone. Zwitterionic polycarboxybetaine coated
surfaces not only resist nonspecific protein adsorption much like polyethylene glycol, but also
provide immobilization sites for biomolecules.[127] Heparin’s action, on the other hand, is
unique as it indirectly inhibits the procoagulant function of soluble thrombin. In theory, the
ideal surface should effectively inhibit thrombin generation, platelet activation, and fibrinogen
adsorption. This is achievable, also in theory, by blocking all contact system proteins and thus
preventing the activation of the blood coagulation cascade. This method of non-specific
protein resistance is an active and well-funded approach which has resulted in reduced blood
activation although surface induced clot formation is still a clinical challenge. Effective
inhibition of thrombin generation, platelet activation, and fibrinogen adsorption could also be
achieved by designer surfaces that target each of those procoagulant elements. Such a surface
could present heparin and some hydrophilic coating and NO release to blood flow.
It is important to point out that as almost all in vitro and in vivo hemocompatibility
assessments of surface modification methods are done in the presence of anticoagulants, most
of the blood-compatibility results are not separated from the effects of anticoagulation.
Moreover, both quantitative and qualitative metrics of the effects of these anticoagulants,
which are administered at known boluses and infusion rates, must be obtained from test
systems that span relevant operating parameters of blood-contacting devices such as flow,
surface area, duration of blood/biomaterial interaction, and geometry of the interacting surface
and material. However, due to the wide variation in surface area and geometry, materials,
flow regime and duration of interaction, metrics observed from the application of many of
these anticoagulants may not be truly comparable from study to study. A presentation of
analyses of their influence on hemocompatibility could accurately be performed largely on a
case by case basis and such exercise would yield a narrative no different from that of the
general state of study to study organization of anticoagulation science, which could be argued
to have contributed to the challenge of gaining deeper insights into their functions and
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comparison. Thus, such analyses have not been included in this review. However, its
importance is acknowledged here by discussing the influence of Citrate commonly used in in
vitro studies, on coagulation properties. The effects of citrate, including those of other
anticoagulants, are increasingly be analyzed by thromboelastography (TEG) to monitor blood
behavior and patient’s hemostasis more and more during surgery. Throbomboelastograhy
mainly measures coagulation time parameters such as R-time (kaolin activated) or TEG-ACT
(tissue factor-TF and kaolin activated), K-time,  angle, maximum amplitude (MA) of tracing,
G-value etc. These parameters in the order listed track accumulation time of clotting factors
(R-time and TEG-ACT), kinetic time for fibrin cross linkage to reach 20 mm clot strength (Ktime) or fibrinogen and platelet numbers, platelet number and function, calculated clot
strength (dyne/cm2) of the entire coagulation cascade. Fibrinolysis could also be analyzed
with TEG by measuring clot lysis at 30 minutes following MA (LY-30).
TEG analysis of citrated blood compared to fresh samples from healthy human subjects
(Table 4) indicated that duration of storage of citrated blood had no effect on TEG analyses
of non-activated or citrated blood activated with kaolin or TF. TEG analyses of fresh non
citrated blood were different from citrated samples. Citrated samples yielded results that were
consistent with a hypercoagulable state. Morever, using kaolin to activate citrated samples
generated results similar results to those obtained from fresh samples. TF gave different
results[133].

Another caution to the reader is the fact that many, but not all, experimental surface
anticoagulation approaches has been traditionally evaluated using single protein and static
condition techniques that do not represent the complexity of blood plasma which contains
many clotting factors that interact with surfaces in a time dependent matnner. Therefore their
effect on blood may or may not be immediately evident. Moreover, many of these studies are
not conducted under flow conditions typical around deployed blood-contacting devices.
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7. Standardization of in vitro and in vivo Test Protocols
Hemocompatibility of artificial surfaces has been traditionally evaluated by analyzing
the surface (protein fouling, platelet adsorption, and clotting factor deposition), accessing the
material property and function based on its intended application (e.g. gas exchange efficiency,
detection specificity and accuracy), and the state of the interacting biological media
(complement activation, platelet function, and white cell counts) perhaps where more work is
needed. As the hemocompatibility of an artificial surface is a function of blood and the
interacting surface, variations in these independent variables can influence hemocompatibility
outcomes and thus must be included in experiment planning in order to obtain a complete
picture of how a surface will perform in clinical trials. The flow chart in Figure 1 is our
attempt to guide the decision making for hemocompatibility testing and perhaps add to the
pre-clinical standardization platform greatly desired by the field. Bulk and molecular
variables of blood such as shear stress, flow regime and stagnation, blood deficiencies,
fouling, platelet function, and inflammation play important roles in surfaces that interact only
with blood (for example gas exchange membranes), as well in surfaces that contact both blood
and tissue (vascular graft, stents, and heart valves). In the latter surface group, however, cell
viability, proliferation, cytotoxicity, and fibrous capsule formation are additional cellular
factors to be considered. Variables as a result of bulk and molecular level properties of the
material or device should also be scrutinized, and they include surface geometry, surface area
to volume ratio, porosity, wettability, material-tissue compliance matching, biodegradation
rate if degradable, toxicity, irritability, sensitivity, and carcinogenicity.
Accordingly, medical devices and biomaterials must undergo rigorous testing, and testing
models, whether in vitro or in vivo, that is as similar as possible to the clinical application
environment. Although animal models are considered expensive and time consuming, they are
needed to bridge the gap between the lab and the clinic. Animal selection for in-vivo studies
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should be based on the advantages and disadvantages for human clinical application.
Importantly, it has been shown that the composition of blood differs considerably between
various species, which leads to over- or under estimation of human blood reactions to
biomaterials.[136,137]
Overall, due to the complexity of blood- biomaterial surfaces interactions and to the
variability in results interpretation among different individuals and species, the clinical
relevance of many studies is still a matter of debate and pose difficulties in standardization.
As the number of publications in the biomedical field increase, the concern for quality
assurance of their results also increase. Since the standardization of materials and devices
testing is crucial and urgent, the International Organization for Standardization (ISO) provides
standards for “Biological evaluation of medical devices” (ISO 10993) although test settings
still vary. It is a 20-part series for evaluating the biocompatibility of medical devices prior to
clinical testing. Evaluation of the biocompatibility and bio-functionality of materials is
conducted by methods based on the assessment of cytotoxicity, mutagenesis/carcinogenesis,
and cell bio-function. Blood-contacting medical devices and biomaterials have to be tested
according to part 4 of the ISO 10993 standard.[138]
The ISO 10993-Part 4 standard is applicable to external communicating devices, either
with an indirect blood path (e.g. blood collection devices, storage systems) or in direct contact
with circulating blood (e.g. catheters, extracorporeal circulation systems), and implant devices
(stents, heart valves, grafts). Testing, according to this standard, should be performed for five
categories, based on primary processes: thrombosis, coagulation, platelets/platelet function,
haematology and complement. For each contact category, primary (Level 1) and optional
(Level 2) tests are recommended. Since testing should simulate clinical conditions as much as
possible, most devices should be tested with heparinized blood under circulating
conditions.[137]
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Regarding hemolysis testing, for devices having direct contact with circulating blood,
it is recommended that both direct and indirect (extract) methods for material/ surfacemediated hemolysis be conducted per ASTM F756 “Standard Practice for Assessment of
Hemolytic Properties of Materials,” or an equivalent method. For hemolysis testing of devices
having indirect contact with circulating blood, it is recommended that only an indirect
(extract) method be conducted per ASTM F756 or an equivalent method. However, for
devices or device components that do not have direct or indirect contact with circulating
blood, this testing is generally not needed. For some devices where high shear stress due to
blood flow may be an issue, dynamic hemolysis assessment under clinical use conditions may
also be important. While ISO 10993-4 is the Hemolysis standard, it can be assessed by any of
several validated methods to assay hemoglobin in plasma to obtain a hemolytic index assessed
by measuring hemoglobin at 1, 2, and 4 hours by spectrophotometric. The hemolysis over this
period is expressed as a percentage of positive control.[137]
Complement activation is the most relevant immunology test for devices exposed to
circulating blood. An increase in a downstream complement component over baseline levels
indicates activation of the complement cascade. Acceptable complement activation limits
have not been established, but comparative data are valuable. For in vitro complement
activation testing, the assessment of C3a, C5a, TCC, Bb, iC3b, C4d, SC5b-9 fragments
activation using an established ELISA test method is recommended. Complement activation
testing whether, in vivo animal models, in vitro “static” methods such as ASTM F1984
“Standard Practice for Testing for Whole Complement Activation in Serum by Solid
Materials,” or in vitro dynamic testing using simulated clinical flow conditions can be used if
accompanied by appropriate validation information.
A device's effects on blood coagulation may be measured in vitro by determining the
rate of clot formation or the partial thromboplastin time of plasma exposed to the biomaterial
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or device during an incubation period. Flow conditions, controls that are being used, and time
of exposure, and the type and concentration of anticoagulation used for in vitro testing, may
depend on the test system and the clinical indication of the device.[137]
Thrombosis may be addressed by performing either an in vivo or ex vivo test. The Lee
White clotting-time test is also sometimes used to satisfy the requirement for a test in this
category. If only a portion of the device is being utilized for thrombogenicity testing, it must
be representative of all materials and important geometrical/surface features that would have
direct contact with the blood. Thrombin-Antithrombin Complex (TAT), Partial
Thromboplastin Time (PTT) are also used as a pseudo substitute for in vivo thrombogenicity
testing. Some of in vitro assessment of thrombogenicity (e.g.the effect of extractables and
leachables on platelets and the coagulation system) may also be needed for devices with
indirect contact with blood.
However, a major problem regarding the use of the ISO 10993/4 standard is the lack
of acceptance criteria and reference materials. There is no totally satisfactory biological test
that can evaluate standard polymers. There are enormous variations between in vivo and in
vitro effects, and these vary too, in different animal species. Although the ISO and the World
Health Organization has published some trials and standards, it is not universally applied
although significant improvements to this standard are underway and being overseen by the
ISO committee.
Overall, because of the complex nature of blood compatibility, a standardized in vitro
hemocompatibility test panel is needed and should enable the detection and elimination of
undesired and excessive material-induced thrombosis and inflammatory events at an early
stage of biomaterial development. Also, since the approval by the currently recommended
panel of tests does not guarantee clinical device/biomaterial hemocompatibility, there is a
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major need for improved in vivo and predictive in vitro test setups. Unsolved concerns also
include the lacking standards for anticoagulation or reference materials.
8. Highlights of Promising Anticoagulation Works
A few surface modification approaches that impart multi-mechanistic anti-coagulation
property have shown highly promising findings. Platelet and fibrinogen adsorption on NO
transferring polymethylethylacrylate coated PU[115], as well as NO transferring PDMS grafted
with polycarboxybetaine[69] have been quantified and shown to highly limit fouling. Similar
anti-clotting activity has been demonstrated with NO-heparin conjugates.[139,140] The NOPMEA and NO-pCB work were conducted on PU and PDMS respectively using flowing NO
gas. In both cases, the PU and PDMS polymers simply transferred NO from a gas supply
while either PU, PVC, or silicone rubber-PU copolymer was used to study the effect NOheparin conjugate on clotting studies. None of the heparin-NO conjugate studies have used
medical grade PDMS as a substrate while PMEA-NO and pCB-NO work have only
transferred NO gas through PDMS. With the pervasive use of PDMS in many bloodcontacting devices due to its biocompatibility and manufacturability[77,141], there are still no
studies that have examined the antifouling properties of NO release with hydrophilic coatings
on this material. Such materials are easily applied via dip coating to surfaces of many bloodcontacting devices including artificial lungs, stents, dialysis membrane, and heart halves.
Antifouling studies using perfluorocarbon (PFC) coatings[77] have been shown to exhibit
nonfouling properties when exposed to blood. PFC is an FDA-approved Teflon-like material
widely used in medical applications including liquid ventilation for infants and blood
substitution. A recent in vivo anti-thrombogenic study of PFC-coated surfaces reported that
the presence of PFC prevented clot formation in pigs for eight hours under high blood flow
rates[77] and without soluble heparin. Another approach geared towards fast screening for
highly protein resistant coatings uses standard poly (ether sulfone) substrates onto which test
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polymers are conjugated through photo-induced graft polymerization using a library of
monomers.[131] Such a screening tools are needed to slingshot the discovery of
thromboresistant surfaces. Devising a practical method for easy attachment of fouling
resistant coatings on medically relevant materials including metals is one of the holy grails in
antifouling surface research. Therefore, the use of a catecholic initiator, for example,
dopamine which was inspired by mussel adhesive proteins, for surface-initiated
polymerization from metallic surfaces to create antifouling polymer coatings was received
with enthusiasm. This approach continues to impact surface modification research as the
catecholic anchor has been used in many surface grafting methods. [142]
9. Conclusion
Interest in surface modification for improved blood-biomaterial interaction is higher
now than a decade ago with more federal funding being poured into this effort. This has in
part led to the highly promising antifouling or antithrombogenic surface developments
although these newer interfaces alone have not yet eliminated the need for systemic
anticoagulation. Thus the risk of life-threatening bleeding complications is still a challenge.
These newer surfaces have focused on single-mechanistic and non-integratie anti-clotting
processes using hydrophilic coatings to resist non-specific protein adsorption, nitric oxide
release from polymers to inhibit platelet activation, and most recently via dual-mechanistic
experimental means. Dual and multi-prong are integrative approaches that draw not only on
the anti-clotting property of each mechanism but also on potential synergies among the
approaches for developing a super anti-clotting material. More work is needed in this area to
understand how the interactions between two or more anti-clotting mechanism would affect
blood coagulation.
Clear and comprehensive standards are also needed for a consistent evaluation of these
surface modification approaches or after their application to devices for easier assessments
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from study to study at both pre-clinical and clinical phases of testing. Factors that will drive
the nature and rigor of pre-clinical testing should focus on the types of interaction between
host’s biological media and surface, duration of contact in the clinical setting so an
appropriate animal model is selected for testing.
So the question of whether totally local anticoagulation on blood-contacting surfaces is
achievable is one that we can definitely address by evaluating all potential solutions.
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Table 1. Agonists secreted from platelets' dense** and alpha* granules including other potent
agonists and their platelet membrane receptors
Agonist
Receptor
**Adenosine diphosphate (ADP) P2Y12 receptor
**Serotonin

5-HT2A receptor (Serotonin receptor)

*Platelet activating factor (PAF)

PAF receptor

*vonWillebrand factor (vWF)

glycoprotein Ib/IX

*Platelet factor 4 (PF4)

PF4 receptor

*Thromboxane A2 (TxA2)

TxA2 receptor

*Thrombin

Protease-activated receptor -1(human)

Collagen

glycoprotein IV

Fibrinogen

glycoprotein IIb/IIIa

Table 2. Surface modification methods for anticoagulation on blood-contacting biomaterials.
Coating
Mechanism
Limitations
Comments
37,74-77
Heparin
Heparin binds to ATIII Limited functionality
Insignificant in infants or
and to form complex.
due to reduced mobility patients with ATIII
Thrombin then attaches and interaction with
deficiency
to complex and loses its ATIII
function
Hydrophilic
Increase hydrophilicity Prone to leach and
coatings (E.g. Sorin, and lower the surface
loses water retention
phosphorylcholine,
energy of biomaterials; during flow
trillium, poly(2limits protein
methoxyethlacryalt) adsorption
37,75

(Self-assembled
monolayers) SAM
coatings77

Biologically active
coatings (E.g. nitric
oxide)37,75

Serves as model
surfaces where alkyl
groups are attached to
metals (usually gold) to
allow attachment of
polymer of interest.
Antibacterial and
antiplatelet agent

Difficulty in forming
ordered monolayer.
largely limited to
model to gold model
surface

Important screening tool
for new polymers

Toxicity; instability
(storage and delivery
complications)

Long term biomaterial
self-release has not been
achieved; no known
effect on protein
adsorption
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Poly(ethylene
oxide)37,75,78

Polyethylene glycol
(PEG) 37,75,78

Albumin-coated
surfaces
37,75

Pyrolytic carboncoated surfaces37,75

Phosphorylcholine
surfaces37,75

Elastin-inspired
coating37,75
Anti-Inflammatory
coatings37,79

Structure repeat unit
(CH2- CH2-O) is able to
form a “liquid like”
surface with active
molecular chains that
have no systematic
molecular order
Very simple structure
(structure repeat unit,
CH2- CH2-O) that
forms a hydrophilic
surface
Coverage of
procoagulant surface.
Plasma protein either
covalently grafted to
the surface or adsorbed
onto pre-tethered long
aliphatic chains (C8C18) or PEO -tether
warfarin
Chemical vapor
deposition in which
hydrocarbon is heated
and graphite layer is
crystallized renders
surfaces hydrophilic

In vitro testing has
been successful;
however, in vivo
testing has been
inconsistent

PEO and PEG are
basically the same
polymer, they are just
derived from different
monomer/polymerization
methods

Coating is easily
influenced by
environmental factors

Hydrophilic and
nontoxic.

Similar anti-fouling
activity in coated and
uncoated grafts

Compared with plasma
proteins such as
fibrinogen and cglobulin, albumin induces
less platelet adhesion
This finding prompted its
use as an inert
thromboresistant coating.

Surface irregularities.
Reduced platelet
adhesion, yet did not
affect overall patency
rate of grafts

No information found on
leaching/other
disadvantages/toxicity.
Preclinical studies
showed no clear benefit

Zwitterionic behavior
allows it to be
electrically neutral at
physiologic pH. Is
known to limit protein
and cell adhesion
Limits platelet adhesion
and aggregation

Unstable coating; No
clear benefit of
coating confirmed

-Passive strategy to
present a nonfouling
surface
-Active strategy by the
active delivery of
antiinflammatory
agents.

- Passive strategies
coatings lack stability
as some proteins can
displace pre-adsorbed
proteins.
- The active strategies
and other novel
approaches (micro and
nanoparticles of
biodegradable
polymers) still require
rigorous testing in in
vivo models

Difficult to isolate and
purify
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Active strategies offer
many advantages over the
passive one. E.g: control
over reaction kinetics,
highly controlled
presentation of
immunomodulatory
agents, versatility through
hybrid systems.

Coatings with
Endothelial Cells
Attachment24,76,80

Endothelial cell
receptor modified
surface for attachment
of cell to create an inert
interface.

Larger than ideal
scaffold surface
microscale topography
cell attachment

Increased interest in
stem-cell directed
endothelialization

Biodegradable
polymers (e.g.
poly(1,8-octanediol
citrate) (POC))24,81

Increased
hydrophilicity

No effect on graft
compliance. Delayed
thrombosis in vitro.

Hydrogel and ionic
liquid based
coatings75,79

Highly resistant to
protein adsorption

Biodegradable
polymers can influence
mechanical properties
of devices such as
vascular grafts and
patches. Porosity may
increase with increased
degradation rate,
increased permeability,
and can decreased
mechanical stiffness in
a nonlinear manner
Inconsistent results of
their effect on reducing
in vivo acute and
chronic
inflammatory responses

Fluoro-Containing
coatings78

Minimization of
surface energy and
surface tension, to
resist fouling.
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Offer many advantages
over traditional strategies,
including a
viscoelasticity, tunable
material characteristics,
incorporation of multiple
chemical functionalities,
nanoscale dimensions
with complex
architectures, and the
ability to deposit onto a
variety of material
substrates.
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Figure 1: Decision making guideline for pre-clinical hemocompatibility testing of
biomaterials
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Biomaterials have and continue to play an important role in how we support and treat patients
with various diseases through their use in tissue and blood interacting medical devices and
drug delivery systems. This review focuses on outstanding challenges and new directions of
anti-clotting biomaterials research.
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ToC figure

ToC figure: Graphical Abstract: An integrative approach to biomaterial surface-focused
anticoagulation for implantable and extracorporeal blood-contacting medical devices.
Examples of synergy benefits from the combination of bioinspired anti-clotting mechanisms
are depicted on surfaces with a) nitric oxide release combined with zwitterionic coating, b)
nitric oxide release with heparin and zwitterionic coatings, and c) nitric oxide release with
heparin coating.
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